KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Asset Writedowns and Impairment (2019 - 2024)

Twist Bioscience (TWST) has disclosed Asset Writedowns and Impairment for 5 consecutive years, with $1.5 million as the latest value for Q3 2023.

  • On a quarterly basis, Asset Writedowns and Impairment fell 91.26% to $1.5 million in Q3 2023 year-over-year; TTM through Sep 2023 was $2.6 million, a 87.22% decrease, with the full-year FY2025 number at -$20000.0, down 102.13% from a year prior.
  • Asset Writedowns and Impairment was $1.5 million for Q3 2023 at Twist Bioscience, up from $454000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $17.5 million in Q3 2022 to a low of -$1.0 million in Q2 2020.
  • A 5-year average of $1.5 million and a median of $383500.0 in 2022 define the central range for Asset Writedowns and Impairment.
  • Peak YoY movement for Asset Writedowns and Impairment: surged 1379.41% in 2022, then tumbled 91.26% in 2023.
  • Twist Bioscience's Asset Writedowns and Impairment stood at $236000.0 in 2019, then increased by 5.08% to $248000.0 in 2020, then skyrocketed by 373.39% to $1.2 million in 2021, then plummeted by 78.36% to $254000.0 in 2022, then surged by 503.54% to $1.5 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's Asset Writedowns and Impairment are $1.5 million (Q3 2023), $454000.0 (Q2 2023), and $332000.0 (Q1 2023).